

The Medical Letter[®]

on Drugs and Therapeutics

Volume 67

September 29, 2025

ISSUE No.
1738

IN THIS ISSUE

Influenza Vaccines for 2025-2026p 153

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying, or any distribution of this material without permission to a nonsubscriber is prohibited.

Sharing a password with a nonsubscriber or otherwise making the contents of this site available to third parties is prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

**For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)
or call customer service at: 800-211-2769**

The Medical Letter®

on Drugs and Therapeutics

Volume 67 (Issue 1738)

September 29, 2025

► Influenza Vaccines for 2025-2026

Annual vaccination against influenza A and B viruses is recommended in the US for everyone ≥ 6 months old without a contraindication.^{1,2} Influenza vaccines available in the US for the 2025-2026 season are listed in Table 2.

COMPOSITION — All influenza vaccines available in the US this season are trivalent: they contain two influenza A virus antigens and one influenza B virus antigen (see Table 1).³ Influenza A viruses are the primary cause of influenza-related morbidity and mortality, especially in older adults. Illness caused by influenza B viruses is usually more severe in children, especially those < 5 years old.⁴ The CDC Advisory Committee on Immunization Practices (ACIP) recommends against use of multidose vaccine formulations this season because they contain the preservative thimerosal.¹

Table 1. 2025-2026 Influenza Vaccine Composition¹

Egg-Based Vaccines

A/Victoria/4897/2022 (H1N1)pdm09-like
A/Croatia/10136RV/2023 (H3N2)-like
B/Austria/1359417/2021 (Victoria lineage)-like

Cell Culture-Based and Recombinant Vaccines

A/Wisconsin/67/2022 (H1N1)pdm09-like
A/District of Columbia/27/2023 (H3N2)-like
B/Austria/1359417/2021 (Victoria lineage)-like

1. All influenza vaccines available in the US for the 2025-2026 influenza season are trivalent. The second influenza B virus strain included in quadrivalent vaccines in recent years has not circulated since March 2020.

TIMING — In the US, vaccination against influenza should ideally be offered in September or October and continue to be offered as long as influenza viruses are circulating in the community. In most adults, serum antibody levels peak 1-2 weeks after vaccination. Vaccination in July or August may result in suboptimal immunity before the end of the influenza season, especially in adults ≥ 65 years old.⁵

The ACIP currently recommends that women who are in their first or second trimester of pregnancy during July or August delay vaccination, if possible, until September or October to ensure that their babies

Key Points: Influenza Vaccines for 2025-2026

- ▶ Annual vaccination against influenza is recommended in the US for everyone ≥ 6 months old without a contraindication.
- ▶ Vaccination should ideally be offered in September or October and continue to be offered as long as influenza viruses are circulating in the community.
- ▶ All influenza vaccines available in the US this season are trivalent; they contain two influenza A virus antigens and one influenza B virus antigen.
- ▶ Influenza vaccination reduces the incidence of laboratory-confirmed influenza and the risk of serious complications and death associated with influenza illness.
- ▶ The ACIP preferentially recommends that adults ≥ 65 years old receive a high-dose (*Fluzone High-Dose*), adjuvanted (*Fluad*), or recombinant (*Flublok*) vaccine.
- ▶ Pregnant women should be vaccinated against influenza.
- ▶ The ACIP states that persons with a history of egg allergy can receive any age-appropriate influenza vaccine. Additional safety measures are no longer recommended for such persons.

are protected throughout the influenza season. Vaccination during July or August can be considered for women who are in their third trimester.¹

Children 6 months to 8 years old who previously received two lifetime doses of an influenza vaccine will only need one dose this season. Those who require two doses should receive the first dose as early as possible so that the second dose can be given by the end of October (see Table 2, footnote 3). Vaccination in September or October is preferred for children of any age who need only one dose, but administration in July or August can be considered.

EFFECTIVENESS — Influenza vaccination reduces the incidence of laboratory-confirmed influenza and the risk of serious complications and death associated with influenza illness.⁶⁻¹⁰ The effectiveness of the seasonal vaccine in preventing influenza illness depends on several factors, including the match between the vaccine and circulating strains and the immunologic response of the recipient. Vaccine effectiveness is greatest when the match is close, but even when it is suboptimal, vaccination can substantially reduce the risk of influenza-related hospitalization and death.¹¹⁻¹³

During the 2024-2025 influenza season in the US, vaccination was associated with up to a 78% reduction in the risk of influenza-associated hospitalization in children and adolescents (interim results).¹⁴

In an observational study in over 1.6 million adults 18-64 years old, a high-dose recombinant vaccine (*Flublok Quadrivalent*) was significantly more effective than standard-dose vaccines in preventing laboratory-confirmed influenza illness.¹⁵

OLDER ADULTS – Older adults are at increased risk for severe influenza illness, hospitalization, and death. They may have a reduced immunogenic response to influenza vaccination compared to younger persons, and their antibody levels may decline more rapidly.¹⁶ Nevertheless, vaccination of older persons has been associated with a reduced risk of influenza-associated and respiratory hospitalization, recurrent hospitalization for ischemic heart disease, and in-hospital death.^{17,18}

High-Dose Vaccine – *Fluzone High-Dose*, an inactivated vaccine that contains 4 times the amount of antigen included in standard-dose inactivated influenza vaccines, is FDA-licensed for use in persons ≥ 65 years old.

In a randomized, double-blind trial in a total of 31,989 adults ≥ 65 years old during two influenza seasons, *Fluzone High-Dose* induced significantly greater antibody responses than a standard-dose inactivated trivalent vaccine and was 24% more effective in preventing laboratory-confirmed influenza illness.¹⁹

In observational studies, meta-analyses, and randomized trials in adults ≥ 65 years old, use of a high-dose inactivated vaccine has been associated with a reduced risk of respiratory-related, cardiovascular-related, and all-cause hospitalization, and death compared to use of a standard-dose inactivated vaccine.²⁰⁻²⁸

In patients with high-risk cardiovascular disease (recent MI or hospitalization for heart failure), use of a high-dose inactivated vaccine elicited greater humoral responses compared to standard-dose inactivated vaccines, but it did not significantly reduce all-cause mortality or cardiopulmonary hospitalizations.^{29,30}

Adjuvanted Vaccine – *Fluad*, an adjuvanted inactivated influenza vaccine, is FDA-licensed for use in persons ≥ 65 years old. It contains MF59, an oil-in-water emulsion of squalene oil that increases the

immune response by recruiting antigen-presenting cells to the injection site and promoting uptake of influenza virus antigens.

In a randomized trial in 7082 adults ≥ 65 years old, *Fluad* elicited significantly greater antibody responses than a nonadjuvanted, standard-dose inactivated vaccine.³¹ In observational studies and randomized trials, older adults who received an adjuvanted inactivated vaccine were less likely to develop symptomatic influenza illness or to be hospitalized for influenza or pneumonia than those who received a nonadjuvanted, standard-dose inactivated vaccine.³²⁻³⁴

Recombinant Vaccine – *Flublok*, a recombinant influenza vaccine produced without use of influenza virus or chicken eggs, contains 3 times the amount of antigen included in standard-dose inactivated influenza vaccines. It is FDA-licensed for use in persons ≥ 9 years old.

In a retrospective cohort study in 12.7 million adults ≥ 65 years old vaccinated during the 2019-2020 influenza season, the recombinant quadrivalent vaccine was more effective in preventing hospital visits than a nonadjuvanted, standard-dose inactivated quadrivalent vaccine, an adjuvanted trivalent vaccine, or a high-dose trivalent vaccine.³⁵

Choice of Vaccine in Older Adults – The ACIP recommends that adults ≥ 65 years old receive either a high-dose (*Fluzone High-Dose*), adjuvanted (*Fluad*), or recombinant (*Flublok*) influenza vaccine; if none of these vaccines are available, any age-appropriate influenza vaccine should be given.¹ Only a few trials have directly compared use of these vaccines in older adults and none have shown that any one is superior to any other.³⁶

PREGNANCY – Vaccination protects pregnant women against influenza-associated illness, which can be especially severe during pregnancy, and protects their infants for up to 6 months after birth (influenza vaccines are not approved for use in infants < 6 months old). Protection is greatest in infants born to mothers who were vaccinated during the third trimester.³⁷

Most studies have not found an association between influenza vaccination and adverse pregnancy outcomes, but data showing vaccination is safe during the first trimester are limited.³⁸ In one prospective study of women who were pregnant or planning to become pregnant, exposure to an influenza vaccine before or during pregnancy was not associated with an increased rate of miscarriage.³⁹

Table 2. Seasonal Influenza Vaccines for 2025-2026

Vaccine ¹	Available Formulations ²	Recommended Age ³	Cost ⁴
Standard-Dose Inactivated Trivalent (IIV3); Egg-based			
<i>Afluria</i> (Seqirus) ⁵	0.5 mL syringe ⁶	≥3 years ⁷	\$21.70
<i>Fluarix</i> (GSK)	0.5 mL syringe ⁸	≥6 months	19.70
<i>FluLaval</i> (GSK)	0.5 mL syringe	≥6 months	19.70
<i>Fluzone</i> (Sanofi)	0.5 mL syringe	≥6 months ⁹	20.10
High-Dose Inactivated Trivalent (HD-IIV3); Egg-based			
<i>Fluzone High-Dose</i> (Sanofi) ¹⁰	0.5 mL syringe	≥65 years ¹¹	78.40
Standard-Dose, Adjuvanted Inactivated Trivalent (aIIV3); Egg-based			
<i>Fluad</i> (Seqirus) ¹²	0.5 mL syringe ¹³	≥65 years ¹¹	78.40
Standard-Dose, Cell Culture-Based Inactivated Trivalent (ccIIV3)			
<i>Flucelvax</i> (Seqirus) ¹⁴	0.5 mL syringe	≥6 months	42.80
Recombinant Trivalent (RIV3)			
<i>Flublok</i> (Sanofi) ¹⁵	0.5 mL syringe	≥9 years	78.40
Live-Attenuated Trivalent (LAIV3); Egg-based			
<i>FluMist</i> (AstraZeneca)	0.2 mL intranasal sprayer ^{8,16,17}	2-49 years ¹⁸	25.40
<i>FluMist Home</i> ¹⁹			67.60 ²⁰

1. All inactivated trivalent vaccines and the recombinant vaccine are given by IM injection. The live-attenuated trivalent vaccine is given intranasally.
2. Sold in boxes of 10. *FluMist* is also available in cartons containing one intranasal sprayer. *Afluria*, *Fluzone*, and *Flucelvax* may be available in multi-dose vials containing thimerosal, but they are not recommended by the ACIP.
3. Children 6 months to 8 years old who are being vaccinated for the first time, whose vaccination history is not known, or who have not received at least 2 lifetime doses of a trivalent or quadrivalent influenza vaccine before July 1, 2025 should receive 2 doses at least 4 weeks apart. The first dose should be given as soon as possible after the vaccine becomes available so that the second dose can be given by the end of October. Children in this age group who received ≥2 doses of a trivalent or quadrivalent influenza vaccine at any time before July 1, 2025 require only 1 dose.
4. Approximate WAC per dose. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. September 5, 2025. Reprinted with permission by First Databank, Inc. All rights reserved. ©2025. www.fdbhealth.com/policies/drug-pricing-policy.
5. Delivery of *Afluria* via the *PharmaJet Stratis* needle-free injection system is FDA-licensed for use in persons 18-64 years old.
6. May contain residual amounts of neomycin sulfate and polymyxin B.
7. The dose is 0.25 mL for children 6-35 months old and 0.5 mL for those ≥3 years old. The 0.25-mL syringes are no longer available.
8. May contain residual amounts of gentamicin sulfate.
9. The dose is either 0.25 mL or 0.5 mL for children 6-35 months old and 0.5 mL for those ≥3 years old. The 0.25-mL prefilled syringes are no longer available; in children 6-35 months old, the dose volume should be 0.5 mL.
10. Contains 60 mcg of hemagglutinin antigen from each strain, compared to 15 mcg in standard-dose inactivated vaccines.
11. The ACIP recommends these vaccines as options for solid organ transplant recipients 18-64 years old who are receiving immunosuppressive therapy.
12. Contains MF59, an oil-in-water emulsion of squalene oil.
13. May contain residual amounts of neomycin and kanamycin.
14. Uses mammalian cells for replication rather than hen eggs.
15. Contains 45 mcg of hemagglutinin antigen from each strain, compared to 15 mcg in standard-dose inactivated vaccines. Contains no egg protein.
16. Each 0.2-mL dose contains 10^{6.5}-10^{7.5} FFU (fluorescent focus units) of live-attenuated influenza virus reassortants from each strain.
17. Each single-use sprayer delivers one 0.2-mL intranasal dose (given as 0.1 mL in each nostril). If nasal congestion that could impair vaccine delivery to the nasal mucosa is present, an injectable vaccine should be used instead. If use of an injectable vaccine is unacceptable, influenza vaccination should be delayed.
18. Per ACIP, the live-attenuated intranasal vaccine is contraindicated for use in patients with a severe allergic reaction to any component of the vaccine or to a previous dose of any influenza vaccine, pregnant women, persons who are immunocompromised, persons with active communication between the cerebrospinal fluid (CSF) and oropharynx, nasopharynx, nose, or ear or any other cranial CSF leak, persons with cochlear implants, children 2-4 years old who have asthma or have had a wheezing episode within the previous 12 months, persons without a functioning spleen, children or adolescents taking aspirin or salicylate-containing therapy, close contacts of severely immunocompromised persons who require a protected environment, or patients treated with oseltamivir or zanamivir within the previous 48 hours, peramivir within the previous 5 days, or baloxavir marboxil within the previous 17 days. Use of influenza antiviral drugs <2 weeks after administration of the intranasal live-attenuated vaccine could inhibit replication of the vaccine virus, reducing the vaccine's effectiveness. Some medical conditions (e.g., renal impairment) may require a longer interval between the antiviral drug regimen and administration of *FluMist*. Patients of any age with asthma may be at increased risk of wheezing after administration of *FluMist*.
19. Available this season in 34 states for home delivery for self-administration or administration by a caregiver.
20. A fee of \$8.99 is added for shipping and processing.

The ACIP and the American College of Obstetricians and Gynecologists (ACOG) recommend vaccinating pregnant women against influenza (see Timing section on page 153).^{1,40,41} The live-attenuated intranasal vaccine (*FluMist*) should not be used during pregnancy.

EGG ALLERGY — The recombinant vaccine (*Flublok*) and the cell culture-based inactivated vaccine (*Flucelvax*) do not contain egg protein. Other available influenza vaccines may contain trace amounts of egg protein (ovalbumin), but numerous studies have found that persons with a history of egg allergy are not at

increased risk for an adverse reaction to influenza vaccines that are propagated in eggs.⁴²

The ACIP, American Academy of Pediatrics (AAP), and Joint Task Force on Practice Parameters of the American Academy of Allergy Asthma and Immunology and the American College of Allergy Asthma and Immunology state that persons with a history of egg allergy of any severity can receive any age-appropriate influenza vaccine without the need for additional safety measures.^{1,2,43} The AAP adds that inquiring about egg allergy before administration of any influenza vaccine is not necessary.²

IMMUNOCOMPROMISED PERSONS — The live-attenuated intranasal influenza vaccine (*FluMist*) should not be used in immunocompromised persons. Inactivated and recombinant influenza vaccines are generally considered safe for use in such persons, but the immune response may be reduced. In two randomized trials in solid-organ transplant recipients, the high-dose vaccine induced significantly greater immune responses than standard-dose inactivated vaccines.^{44,45} The ACIP states that the trivalent high-dose inactivated vaccine (*Fluzone High-Dose*) and trivalent adjuvanted inactivated influenza vaccine (*Fluad*) are acceptable options for solid-organ transplant recipients 18-64 years old who are receiving immunosuppressive therapy.¹ Separating the time of influenza vaccination from that of an immunocompromising intervention could be considered.

USE WITH OTHER VACCINES — Any influenza vaccine can be given at the same time as a **COVID-19 vaccine**, but they should be administered in separate arms. The ACIP states that coadministration of a **respiratory syncytial virus (RSV)** vaccine with other adult vaccines during the same visit is acceptable. RSV and influenza antibody titer levels are somewhat lower with coadministration than with sequential administration (~1 month apart).⁴⁶

Inactivated and **recombinant** influenza vaccines can be administered concomitantly or sequentially with live, inactivated, or recombinant vaccines. The **live-attenuated** intranasal influenza vaccine can be given simultaneously with inactivated or other live vaccines; other live vaccines not administered simultaneously should be given at least 4 weeks later. Because of limited safety data on concurrent use of 2 or more **adjuvanted** vaccines, use of a nonadjuvanted influenza vaccine may be considered when another adjuvanted vaccine (e.g., *Shingrix*, *Heplisav-B*) is administered concurrently.

USE WITH INFLUENZA ANTIVIRALS — Any inactivated or recombinant influenza vaccine can be administered to persons receiving antiviral drugs for treatment or chemoprophylaxis of influenza. Use of oseltamivir (*Tamiflu*, and generics) or zanamivir (*Relenza*) within 48 hours before, peramivir (*Rapivab*) within 5 days before, or baloxavir marboxil (*Xofluza*) within 17 days before administration of the live-attenuated intranasal influenza vaccine could inhibit replication of the vaccine virus, reducing its effectiveness. Persons who receive any of these antiviral drugs during these

specified times or within 2 weeks after administration of the live-attenuated vaccine should be revaccinated with an inactivated or recombinant influenza vaccine.

ADVERSE EFFECTS — Influenza vaccination has been associated with Guillain-Barré syndrome, but the absolute risk is very low (about 1-2 additional cases per million persons vaccinated), and influenza infection itself has been associated with the syndrome (about 17 cases per million patients hospitalized with influenza).⁴⁷ In a prospective cohort study in patients with diabetes, influenza vaccination was associated with hyperglycemia, but serum glucose levels returned to baseline 2 days after vaccination.⁴⁸

Except for soreness at the injection site, adverse reactions to **inactivated** influenza vaccines are uncommon. In clinical trials, the **high-dose** vaccine (*Fluzone High-Dose*) caused more injection-site reactions than standard-dose influenza vaccines. Pain and tenderness at the injection site also occurred more frequently with an **adjuvanted** vaccine (*Fluad*) than with a nonadjuvanted vaccine. Delivery of *Afluria* by needle-free jet injector has resulted in more mild to moderate local reactions than delivery by standard needle and syringe.

The most common adverse reactions associated with the **live-attenuated** intranasal vaccine are runny nose, nasal congestion, fever, and sore throat. The vaccine may increase the risk of wheezing, especially in children <5 years old with recurrent wheezing and in persons of any age with asthma. Persons who receive the live-attenuated vaccine may shed the vaccine-strain virus for a few days after vaccination, but person-to-person transmission has been rare, and serious illness resulting from transmission has not been reported. Nevertheless, the ACIP recommends that persons who care for severely immunocompromised patients in protected environments avoid contact with such patients for 7 days after receiving the live-attenuated vaccine.¹ ■

1. LA Grohskopf et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices – United States, 2025-2026 influenza season. *MMWR Recomm Rep* 2025; 74:500.
2. Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2025-2026: policy statement. *Pediatrics* 2025 July 28 (epub).
3. AS Monto et al. The end of B/Yamagata influenza transmission – transitioning from quadrivalent vaccines. *N Engl J Med* 2024; 390:1256.
4. YR Bhat. Influenza B infections in children: a review. *World J Clin Pediatr* 2020; 9:44.

5. JM Ferdinands et al. Waning vaccine effectiveness against influenza-associated hospitalizations among adults, 2015-2016 to 2018-2019, United States Hospitalized Adult Influenza Vaccine Effectiveness Network. *Clin Infect Dis* 2021; 73:726.
6. C Arriola et al. Influenza vaccination modifies disease severity among community-dwelling adults hospitalized with influenza. *Clin Infect Dis* 2017; 65:1289.
7. B Flannery et al. Influenza vaccine effectiveness against pediatric deaths: 2010-2014. *Pediatrics* 2017; 139:e20164244.
8. AP Campbell et al. Effect of vaccination on preventing influenza-associated hospitalizations among children during a severe season associated with B/Victoria viruses, 2019-2020. *Clin Infect Dis* 2021; 73:e947.
9. S Garg et al. Influenza vaccination reduces risk of severe outcomes among adults hospitalized with influenza A(H1N1)pdm09, FluSurv-NET, 2013-2018. *Open Forum Infect Dis* 2019; 6(Suppl 2):S26.
10. SM Olson et al. Vaccine effectiveness against life-threatening influenza illness in US children. *Clin Infect Dis* 2022; 75:230.
11. M Darvishian et al. Effectiveness of seasonal influenza vaccine in community-dwelling elderly people: a meta-analysis of test-negative design case-control studies. *Lancet Infect Dis* 2014; 14:1228.
12. NM Lewis et al. Vaccine effectiveness against influenza A-associated hospitalization, organ failure, and death: United States, 2022-2023. *Clin Infect Dis* 2024; 78:1056.
13. LC Sahni et al. Sustained within-season vaccine effectiveness against influenza-associated hospitalization in children: evidence from the New Vaccine Surveillance Network, 2015-2016 through 2019-2020. *Clin Infect Dis* 2023; 76:e1031.
14. AM Frutos et al. Interim estimates of 2024-2025 seasonal influenza vaccine effectiveness – four vaccine effectiveness networks, United States, October 2024-February 2025. *MMWR Morb Mortal Wkly Rep* 2025; 74:83.
15. A Hsiao et al. Recombinant or standard-dose influenza vaccine in adults under 65 years of age. *N Engl J Med* 2023; 389:2245.
16. B Young et al. Do antibody responses to the influenza vaccine persist year-round in the elderly? A systematic review and meta-analysis. *Vaccine* 2017; 35:212.
17. Y Pang et al. Effectiveness of influenza vaccination on in-hospital death and recurrent hospitalization in older adults with cardiovascular diseases. *Int J Infect Dis* 2022; 122:162.
18. Z-Y Peng et al. Reduced risks of influenza-associated hospitalization and complications following vaccination among over 2 million older individuals: a nationwide study using target trial emulation framework. *BMC Med* 2025; 23:157.
19. CA DiazGranados et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. *N Engl J Med* 2014; 371:635.
20. S Gravenstein et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccination on numbers of US nursing home residents admitted to hospital: a cluster-randomised trial. *Lancet Respir Med* 2017; 5:738.
21. DK Shay et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines among US Medicare beneficiaries in preventing postinfluenza deaths during 2012-2013 and 2013-2014. *J Infect Dis* 2017; 215:510.
22. KG Skaarup et al. The relative vaccine effectiveness of high-dose vs standard-dose influenza vaccines in preventing hospitalization and mortality: a meta-analysis of evidence from randomized trials. *J Infect* 2024; 89:106187.
23. JKH Lee et al. Efficacy and effectiveness of high-dose influenza vaccine in older adults by circulating strain and antigenic match: an updated systematic review and meta-analysis. *Vaccine* 2021; 39(Suppl 1):A24.
24. Y Young-Xu et al. High-dose influenza vaccination and mortality among predominantly male, white, senior veterans, United States, 2012/13 to 2014/15. *Euro Surveill* 2020; 25:1900401.
25. ND Johansen et al. A pragmatic randomized feasibility trial of influenza vaccines. *NEJM Evid* 2023; 2:EVIDoa2200206.
26. J Pardo-Seco et al. High-dose influenza vaccine to reduce hospitalizations. *N Engl J Med* 2025 August 30 (epub).
27. ND Johansen et al. High-dose influenza vaccine effectiveness against hospitalization in older adults. *N Engl J Med* 2025 August 30 (epub).
28. ND Johansen et al. High-dose vs standard-dose influenza vaccine and cardiovascular outcomes in older adults: a pre-specified secondary analysis of the DANFLU-2 randomized clinical trial. *JAMA Cardiol* 2025 August 30 (epub).
29. O Vardeny et al. Effect of high-dose trivalent vs standard-dose quadrivalent influenza vaccine on mortality or cardiopulmonary hospitalization in patients with high-risk cardiovascular disease: a randomized clinical trial. *JAMA* 2021; 325:39.
30. A Peikert et al. Influenza vaccine immune response in patients with high-risk cardiovascular disease: a secondary analysis of the INVESTED randomized clinical trial. *JAMA Cardiol* 2024; 9:574.
31. SE Frey et al. Comparison of the safety and immunogenicity of an MF59-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects. *Vaccine* 2014; 32:5027.
32. PG Van Buynder et al. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. *Vaccine* 2013; 31:6122.
33. F Lapi et al. Adjuvanted versus nonadjuvanted influenza vaccines and risk of hospitalizations for pneumonia and cerebro/cardiovascular events in the elderly. *Expert Rev Vaccines* 2019; 18:663.
34. KW McConeghy et al. Cluster-randomized trial of adjuvanted versus nonadjuvanted trivalent influenza vaccine in 823 US nursing homes. *Clin Infect Dis* 2021; 73:e4237.
35. HS Izurieta et al. Comparative effectiveness of influenza vaccines among US Medicare beneficiaries ages 65 years and older during the 2019-2020 season. *Clin Infect Dis* 2021; 73:e4251.
36. JH Ku et al. Comparative effectiveness of licensed influenza vaccines in preventing influenza-related medical encounters and hospitalizations in the 2022-2023 influenza season among adults ≥65 years of age. *Clin Infect Dis* 2024; 79:1283.
37. LC Sahni et al. Maternal vaccine effectiveness against influenza-associated hospitalizations and emergency department visits in infants. *JAMA Pediatr* 2024; 178:176.
38. A Mehrabadi et al. Association of maternal influenza vaccination during pregnancy with early childhood health outcomes. *JAMA* 2021; 325:2285.
39. AK Regan et al. Risk of miscarriage in relation to seasonal influenza vaccination before or during pregnancy. *Obstet Gynecol* 2023; 142:625.
40. CDC. Influenza vaccine safety considerations during pregnancy or while breastfeeding. January 16, 2025. Available at: <https://bit.ly/46b12Am>. Accessed September 11, 2025.

41. ACOG. Influenza in pregnancy: prevention and treatment. ACOG Committee Statement No. 7. Obstet Gynecol 2024; 143:e24.
42. M Greenhawt et al. Administration of influenza vaccines to egg allergic recipients: a practice parameter update 2017. Ann Allergy Asthma Immunol 2018; 120:49.
43. American Academy of Allergy Asthma & Immunology. Egg allergy and the flu vaccine. August 13, 2025. Available at: <https://bit.ly/3JS9v45>. Accessed September 11, 2025.
44. Y Natori et al. A double-blind, randomized trial of high-dose vs standard-dose influenza vaccine in adult solid-organ transplant recipients. Clin Infect Dis 2018; 66:1698.
45. AG L'huillier et al. Cell-mediated immune responses after influenza vaccination of solid organ transplant recipients: secondary outcomes analyses of a randomized controlled trial. J Infect Dis 2020; 221:53.
46. M Melgar et al. Use of respiratory syncytial virus vaccines in older adults: recommendations of the Advisory Committee on Immunization Practices – United States, 2023. MMWR Morb Mortal Wkly Rep 2023; 72:793.
47. A Babazadeh et al. Influenza vaccination and Guillain-Barré syndrome: reality or fear. J Transl Int Med 2019; 7:137.
48. AL Hulsizer et al. Hyperglycemia post-influenza vaccine in patients with diabetes. Ann Pharmacother 2023; 57:51.

PRESIDENT: Mark Abramowicz, M.D.; **VICE PRESIDENT:** Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School; **VICE PRESIDENT, EDITOR IN CHIEF:** Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Dartmouth Hitchcock Medical Center; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli
EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:
 The Medical Letter, Inc.
 2 Madison Ave, Ste 211
 Larchmont, NY 10538
www.medicalletter.org

Customer Service:
 Call: 800-211-2769 or 914-235-0500
 Fax: 914-632-1733
 E-mail: custserv@medicalletter.org

Permissions:
 To reproduce any portion of this issue,
 please e-mail your request to:
permissions@medicalletter.org

Subscriptions (US):
 1 year – \$179; \$65 per year
 for students, interns, residents,
 and fellows in the US and Canada.
 Reprints – \$45 per issue or article

Site License Inquiries:
 E-mail: SubQuote@medicalletter.org
 Call: 800-211-2769
 Special rates available for bulk
 subscriptions.

Get Connected: 

Copyright 2025. ISSN 0025-732X

The
 Medical
 Letter